Bruker Corporation $BRKR Shares Bought by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. lifted its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 741.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 9,522 shares of the medical research company’s stock after purchasing an additional 8,391 shares during the period. Rockefeller Capital Management L.P.’s holdings in Bruker were worth $449,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Royal Bank of Canada raised its position in Bruker by 8.3% in the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after acquiring an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Bruker during the 1st quarter worth $262,000. Goldman Sachs Group Inc. increased its holdings in shares of Bruker by 107.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after purchasing an additional 758,301 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Bruker by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock valued at $15,285,000 after purchasing an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth lifted its stake in shares of Bruker by 115.0% in the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock valued at $469,000 after purchasing an additional 6,008 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BRKR. JPMorgan Chase & Co. upped their target price on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. TD Cowen upped their price target on Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a report on Thursday, May 7th. Stifel Nicolaus set a $45.00 price objective on Bruker in a research note on Friday, May 8th. Finally, Citigroup lifted their price objective on Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $54.54.

Bruker Stock Performance

NASDAQ:BRKR opened at $61.64 on Monday. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $9.38 billion, a P/E ratio of -256.83, a price-to-earnings-growth ratio of 1.97 and a beta of 1.29. The firm has a 50-day moving average price of $50.57 and a two-hundred day moving average price of $45.01. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $64.54.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The business had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. During the same period in the prior year, the business earned $0.47 earnings per share. The company’s quarterly revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts expect that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 22nd. This represents a $0.20 annualized dividend and a yield of 0.3%. Bruker’s dividend payout ratio (DPR) is presently -83.33%.

Insiders Place Their Bets

In other news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 27.20% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.